CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

ID Week 2023

October 11-15, 2023
Boston, Massachusetts

  • Cabotegravir Treatment

    Garris C, et al.

    Real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study

    View Poster

    Sinclair G, et al.

    Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)

    View Poster

    Dandachi D, et al.

    Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)

    View Poster

    McKellar MS, et al.

    SOLAR 12-month North American results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF

    View Poster

  • Cabotegravir Prevention

    Torres JA, et al.

    Healthcare staff perceptions of feasibility and acceptability on implementing injectable HIV pre-exposure prophylaxis into standard of care: baseline results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)

    View Poster

    Richmond T, et al.

    Engaging black women on cabotegravir LA for PrEP by optimizing novel implementation strategies (EBONI) study: provider perceptions of appropriateness cabotegravir LA for PrEP for cis- and- trans black women

    View Poster

    Valenti W, et al.

    Integrating long-acting injectable cabotegravir for PrEP into standard of care for cisgender women, transgender women, transgender men, and men who have sex with men: results from the PILLAR & EBONI studies

    View Poster

    Davis W, et al.

    Acceptability of an HIV pre-exposure prophylaxis (PrEP) shared decision-making tool for diverse populations and healthcare providers

    View Poster

    Kerrigan D, et al.

    Exploring cisgender women's HIV pre-exposure prophylaxis (PrEP) needs and preferences across settings: the role of social-structural factors

    View Poster

    Poteat T, et al.

    Risk Factors, Risk Perception, and Long-acting PrEP Awareness and Interest among US Women: A National Survey

    View Poster

  • Dolutegravir-based Regimens

    Brogan AP, et al.

    Virological Suppression in People with HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis)

    View Poster

  • Fostemsavir Treatment

    Dyson A, et al.

    Durable efficacy and robust CD4+ T-Cell count improvement observed among age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment

    View Poster

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.